CCI
CLDX icon

Columbus Circle Investors’s Celldex Therapeutics CLDX Stock Holding History

Columbus Circle Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43,716
Closed -$10.3M – 273
2015
Q4 		$10.3M Buy
43,716
+4,150
+10% +$905K 0.08% 197
2015
Q3 		$6.25M Sell
39,566
-5,036
-11% -$1.43M 0.05% 218
2015
Q2 		$16.9M Sell
44,602
-18,786
-30% -$7.46M 0.12% 183
2015
Q1 		$26.5M Sell
63,388
-45,153
-42% -$16.2M 0.18% 123
2014
Q4 		$29.7M Buy
108,541
+34,833
+47% +$8.66M 0.21% 110
2014
Q3 		$14.3M Sell
73,708
-19,656
-21% -$4.28M 0.1% 170
2014
Q2 		$22.9M Sell
93,364
-24,425
-21% -$5.51M 0.16% 135
2014
Q1 		$31.2M Sell
117,789
-28,161
-19% -$10.8M 0.21% 121
2013
Q4 		$53M Buy
145,950
+15,996
+12% +$6.16M 0.36% 85
2013
Q3 		$69.1M Sell
129,954
-32,904
-20% -$11.3M 0.49% 64
2013
Q2 		$38.1M Buy
+162,858
New +$32.1M 0.31% 89

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Columbus Circle Investors's CLDX Position: Q1 2016 in Review

Columbus Circle Investors sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 43,716 shares — an estimated $10.3M sold.

Columbus Circle Investors first reported a position in CLDX in Q2 2013 and held it in 11 quarters. The position peaked at $69.1M in Q3 2013. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Columbus Circle Investors reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Columbus Circle Investors sold 43,716 Celldex Therapeutics shares in Q1 2016, an estimated $10.3M.
  • Columbus Circle Investors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 11 quarters.
  • Columbus Circle Investors's Celldex Therapeutics position peaked at $69.1M in Q3 2013.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Columbus Circle Investors's 13F filing for Q1 2016, filed 3 May 2016.